PathAI’s $165 Million Series C Financing

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Tiger Global on the deal.

PathAI, a global provider of artificial intelligence-powered technology for pathology, announced the closing of its $165 million Series C financing. PathAI will deploy its new capital to accelerate product development while continuing to prioritize the improvement of patient outcomes with reliable AI-powered technology and meaningful collaboration with pharmaceutical and diagnostic partners.

The funds will expand the PathAI product suite and commercial footprint to enhance the full lifecycle of the drug development process from translational and exploratory research to global commercialization. PathAI will further develop a broad menu of AI-based pathology offerings for biopharma into disease indications beyond oncology and NASH while also developing a scalable workflow platform for CROs and reference lab partners.

This Series C financing round was co-led by D1 Capital Partners and by Kaiser Permanente, one of America’s leading health care providers and not-for-profit health plans. Other investors included General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital and strategic partners Bristol-Myers Squibb Company, Labcorp and Merck Global Health Innovation Fund (GHI).

The Gunderson deal team was led by Steve Baglio (Picture) and included Bennett Yee, Mark Oblad and Jake Winton.

Involved fees earner: Steven Baglio – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian; Mark Oblad – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian; Jake Winton – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian; Bennett Yee – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian;

Law Firms: Gunderson Dettmer Stough Villeneuve Franklin & Hachigian;

Clients: Tiger Global Management;

Martina Bellini

Author: Martina Bellini